Literature DB >> 22047156

Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system.

Zheng Jia1, Sihong Xu, Jianhui Nie, Jingyun Li, Ping Zhong, Wenbo Wang, Youchun Wang.   

Abstract

BACKGROUND AND OBJECTIVES: Drug resistance in HIV-1 is one of the main causes of failure of antiretroviral therapy. Phenotypic detection of drug-resistant HIV-1 can provide guidance in selecting the optimal treatment regimen. Traditional phenotype assays are labor intensive and time consuming. Thus, a rapid and convenient phenotype assay with a single cycle of replication was developed and used in this study.
METHODS: Two restriction endonuclease sites, ApaI and AgeI, were inserted into the plasmid pSG3Δenv(,) using site-directed mutagenesis. The reverse transcriptase and protease genes of HIV-1 were amplified from patients and cloned into the modified pSG3Δenv. Sixteen original recombinant pseudoviruses were generated. The phenotypic susceptibility of these 16 recombinant pseudoviruses to 12 antiretroviral drugs was determined using a luciferase reporter system, and the phenotype and genotype results were compared.
RESULTS: A modified phenotype assay with a single-cycle system was established, and its reproducibility and feasibility were validated. Approximately 89% of the phenotype results were in agreement with the genotype results; this slight disagreement may have been due to complex and multiple resistance mutations. The phenotype results showed that individual pseudoviruses with four thymidine analog mutations (TAMs).[M41L, T67N, L210W, and T215Y] in combination with various other mutations had different levels of resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Mutations E44A, T69D, and V118I influenced the pattern of resistance of TAMs. The level of resistance to non-NRTIs (NNRTIs) was also variable when different NNRTI-resistance mutations were combined.
CONCLUSION: The single-cycle pseudovirus phenotypic susceptibility detection system reflects HIV-1 drug resistance, especially for complex resistance mutants, and could be used to screen new antiretroviral candidates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22047156     DOI: 10.1007/bf03256421

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  30 in total

1.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

Review 2.  Antiretroviral drug resistance and resistance testing.

Authors:  Joel E Gallant
Journal:  Top HIV Med       Date:  2005 Dec-2006 Jan

3.  Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation.

Authors:  Bradley J Betts; Robert W Shafer
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.

Authors:  Huihui Chong; Kunxue Hong; Chuntao Zhang; Jianhui Nie; Aijing Song; Wei Kong; Youchun Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

6.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sophie Le Coeur; Chureeratana Bowonwatanuwong; Pacharee Kantipong; Pranee Leechanachai; Surabhon Ariyadej; Prattana Leenasirimakul; Scott Hammer; Marc Lallemant
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

7.  Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.

Authors:  Seble Kassaye; Esther Lee; Rami Kantor; Elizabeth Johnston; Mark Winters; Lynn Zijenah; Patrick Mateta; David Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  2007-08       Impact factor: 2.205

8.  Isolation and quantitation of HIV in peripheral blood.

Authors:  R A Koup; D D Ho; G Poli; A S Fauci
Journal:  Curr Protoc Immunol       Date:  2001-05

9.  Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.

Authors:  Zehava Grossman; Valery Istomin; Diana Averbuch; Margalit Lorber; Klaris Risenberg; Itzchak Levi; Michael Chowers; Michael Burke; Nimrod Bar Yaacov; Jonathan M Schapiro
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

10.  Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.

Authors:  Francesca Ceccherini-Silberstein; Valentina Svicher; Tobias Sing; Anna Artese; Maria Mercedes Santoro; Federica Forbici; Ada Bertoli; Stefano Alcaro; Guido Palamara; Antonella d'Arminio Monforte; Jan Balzarini; Andrea Antinori; Thomas Lengauer; Carlo Federico Perno
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

View more
  2 in total

1.  A simple and cost-saving phenotypic drug susceptibility testing of HIV-1.

Authors:  Yunceng Weng; Ling Zhang; Jianfeng Huang; Jin Zhao; Peifang Luo; Siyuan Bi; Zhengrong Yang; Hai Zhu; Jean-Pierre Allain; Chengyao Li
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

Review 2.  HIV-1 pseudoviruses constructed in China regulatory laboratory.

Authors:  Jianhui Nie; Weijin Huang; Qiang Liu; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2019-12-20       Impact factor: 7.163

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.